Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Zealand Pharma

505.80 DKK

+2.49 %

Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+2.49 %
+4.25 %
+13.56 %
+8.54 %
-29.31 %
-30.71 %
+141.32 %
+123.02 %
+536.23 %

Zealand Pharma is a biotechnology company. Particular focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest business is in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Söborg, Denmark.

Read more
Market cap
36.1B DKK
Turnover
124.73M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release11/13/2025, 6:00 AM

Zealand Pharma Announces Financial Results for the First Nine Months of 2025

Zealand Pharma
Regulatory press release10/17/2025, 3:05 PM

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Zealand Pharma
Regulatory press release9/30/2025, 3:05 PM

Total number of shares and voting rights in Zealand Pharma as of September 30, 2025

Zealand Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release9/11/2025, 8:00 PM

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma
Press release8/28/2025, 3:00 PM

Zealand Pharma to participate in upcoming investor conferences in September 2025

Zealand Pharma
Regulatory press release8/20/2025, 8:00 PM

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Zealand Pharma
Regulatory press release8/14/2025, 5:00 AM

Zealand Pharma Announces Financial Results for the First Half of 2025

Zealand Pharma
Press release8/7/2025, 3:30 PM

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

Zealand Pharma
Regulatory press release7/18/2025, 4:30 PM

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Zealand Pharma
Regulatory press release6/30/2025, 3:05 PM

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

Zealand Pharma
Regulatory press release6/18/2025, 3:29 PM

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

Zealand Pharma
Regulatory press release6/6/2025, 8:00 PM

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma
Press release6/2/2025, 5:00 AM

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

Zealand Pharma
Regulatory press release5/27/2025, 8:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Press release5/19/2025, 1:00 PM

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

Zealand Pharma
Press release5/12/2025, 5:00 AM

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025

Zealand Pharma
Regulatory press release5/9/2025, 4:24 AM

Zealand Pharma announces closing of collaboration and license agreement with Roche

Zealand Pharma
Regulatory press release5/8/2025, 5:00 AM

Zealand Pharma Announces Financial Results for the First Three Months of 2025

Zealand Pharma
Press release5/1/2025, 3:05 PM

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

Zealand Pharma
Press release4/24/2025, 5:00 AM

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Zealand Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.